Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 22096 AL 22110

Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease

Armentero MT, Sinforiani E, Ghezzi C, Bazzini E, Levandis G, Ambrosi G, Zangaglia R, Pacchetti C, Cereda C, Cova E, Basso E, Celi D, Martignoni E, Nappi G, Blandini F.

Neurobiol Aging. 2011 Dec;32(12):2142-51. doi: 10.1016/j.neurobiolaging.2010.01.004. Epub 2010 Jan 27.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16.

Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation

Habek M, Hajnsek S, Zarković K, Chudy D, Mubrin Z.

Can J Neurol Sci. 2010 Jan;37(1):118-20.

Microglia activation and anti-inflammatory regulation in Alzheimer's disease

Lue LF, Kuo YM, Beach T, Walker DG.

Mol Neurobiol. 2010 Jun;41(2-3):115-28. doi: 10.1007/s12035-010-8106-8. Epub 2010 Mar 3.

[Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease]

Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pampliega-Pérez A, Montoya-Gutiérrez J, Leiva-Santana C.

Rev Neurol. 2010 Feb 16-28;50(4):193-200.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131.

Impact of the CD40-CD40L dyad in Alzheimer's disease

Giunta B, Rezai-Zadeh K, Tan J.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.

Alzheimer's disease and retinal neurodegeneration

Guo L, Duggan J, Cordeiro MF.

Curr Alzheimer Res. 2010 Feb;7(1):3-14. doi: 10.2174/156720510790274491.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

[Diagnosis of Alzheimer's disease]

Derouesné C.

Psychol Neuropsychiatr Vieil. 2010 Mar;8(1):5-6. doi: 10.1684/pnv.2010.0202.

[What use of biological markers for the diagnosis of Alzheimer's disease and associated disorders?]

Krolak-Salmon P.

Psychol Neuropsychiatr Vieil. 2010 Mar;8(1):25-31. doi: 10.1684/pnv.2009.0189.

[Importance of molecular diagnostics in Alzheimer dementia. A case report]

Honneth J, Nehen HG, Haseke J.

Z Gerontol Geriatr. 2010 Jun;43(3):177-9. doi: 10.1007/s00391-010-0101-1. Epub 2010 Apr 1.

Cerebrospinal fluid biomarkers of Alzheimer's disease

Fagan AM, Holtzman DM.

Biomark Med. 2010 Feb;4(1):51-63. doi: 10.2217/BMM.09.83.

Aging and lateralization of the rat brain on a biochemical level

Kristofiková Z, Rícný J, Ort M, Rípová D.

Neurochem Res. 2010 Aug;35(8):1138-46. doi: 10.1007/s11064-010-0165-8. Epub 2010 Apr 6.

Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease

Rabinovici GD, Roberson ED.

Ann Neurol. 2010 Mar;67(3):283-5. doi: 10.1002/ana.22020.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias